brimonidine (UK14304)   Click here for help

GtoPdb Ligand ID: 520

Synonyms: Alphagan® | Lumify® | Mirvaso® | UK14,304 | UK14304
Approved drug PDB Ligand Immunopharmacology Ligand
brimonidine (UK14304) is an approved drug (FDA (1996), EMA (2014))
Compound class: Synthetic organic
Comment: Brimonidine is an α-adrenoceptor agonist (primarily α2).
Click here for help
IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: brimonidine

2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 5
Hydrogen bond donors 2
Rotatable bonds 2
Topological polar surface area 62.2
Molecular weight 291.01
XLogP 1.18
No. Lipinski's rules broken 0
Click here for help
Canonical SMILES Brc1c(ccc2c1nccn2)NC1=NCCN1
Isomeric SMILES Brc1c(ccc2c1nccn2)NC1=NCCN1
InChI InChI=1S/C11H10BrN5/c12-9-7(17-11-15-5-6-16-11)1-2-8-10(9)14-4-3-13-8/h1-4H,5-6H2,(H2,15,16,17)
No information available.
Summary of Clinical Use Click here for help
Used in the treatment of glaucoma. Low dose brimonidine tartrate (0.025%) ophthalmic solution is effective against ocular redness. EMA approval authorises use in the treatment of facial skin erythema in rosacea.
Mechanism Of Action and Pharmacodynamic Effects Click here for help
Brimonidine appears to reduce intraocular pressure by reducing both aqueous humor production and outflow from the eyeball.
External links Click here for help